ExpreS2ion Biotech Holding AB
STO:EXPRS2
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.52
30.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ExpreS2ion Biotech Holding AB
Research & Development
ExpreS2ion Biotech Holding AB
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Research & Development
-kr14.1m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Research & Development
-kr112.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Research & Development
-kr89.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Research & Development
-kr102m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-6%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Research & Development
-kr3.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-20%
|
|
|
BioArctic AB
STO:BIOA B
|
Research & Development
-kr311.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Research & Development?
Research & Development
-14.1m
SEK
Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Research & Development amounts to -14.1m SEK.
What is ExpreS2ion Biotech Holding AB's Research & Development growth rate?
Research & Development CAGR 3Y
26%
Over the last year, the Research & Development growth was 52%. The average annual Research & Development growth rates for ExpreS2ion Biotech Holding AB have been 26% over the past three years .